Empowering pharmaceutical innovators with advanced delivery solutions.

For over 2 decades, we’ve enabled pharma innovators to develop, scale, and launch high-quality solid dosage forms across global markets. With a strong scientific backbone and a commitment to excellence, we continuously strive to transform complex formulations into commercial success.

Our Journey

2004

The journey began with the establishment of a service-oriented foundation focused on direct consumer care and improving accessibility within the healthcare sector.

2009

The service footprint experienced rapid growth, expanding into a network of over 80 locations. This phase provided critical insights into market demand and end-user needs.

2012

Operations expanded beyond the retail level to include a large-scale logistics and supply chain arm, enabling nationwide delivery across 42 states.

2016

To support a vertically integrated model, the group established an in-house manufacturing facility. This allowed for greater control over the production process and the quality of specialized health products.

2024

The group significantly enhanced its technical capabilities by acquiring a fully licensed Health Canada and USFDA pharma facility dedicated to research and specialized manufacturing, focusing on complex formulations.

2025

Medicap Laboratories achieved operational capacity in advanced research and manufacturing, establishing a global footprint to deliver science-driven solutions across international markets.

Our Facility

Medicap’s expansive GMP-compliant site offers a modern, scalable platform for oral solid dosage development which supports projects from early-stage specialty molecule formulation through to commercial production. The facility integrates advanced research labs, analytical suites, and validated manufacturing cleanrooms, enabling fast, compliant, and high-quality product delivery for domestic and global markets.

With over 10 proprietary patents and an expanding portfolio of differentiated release technologies, the group continues to invest in innovation, regulatory excellence, and scientific capability ensuring that every part of the supply chain works in harmony to deliver value for partners and better outcomes for patients.

By capturing every stage of the pharmaceutical lifecycle from retail and distribution to manufacturing and R&D we are building a fully integrated ecosystem designed to deliver speed, flexibility, and strategic advantage to our clients worldwide.

Our Team

Our Team

At the heart of our leadership philosophy is a belief in transparency, accountability, and science-led execution. Each engagement is personally overseen by leadership to ensure alignment, responsiveness, and strategic continuity. We don’t just deliver we collaborate, adapt, and evolve with our partners.

Medicap is led by a seasoned team of pharmaceutical scientists, regulatory strategists, and industry executives with deep roots in product development and commercialization. Our leadership brings decades of experience managing end-to-end CDMO operations from early-phase research and regulatory engagement to global product launches.

Why Choose Us ?

We offer the best of both worlds: the operational excellence of a mature CDMO and the responsiveness of a boutique firm.

Our value lies not just in what we do, but in how we do it with scientific precision, flexible engagement models, and a relentless commitment to our clients’ success.

We specialize in complex oral delivery systems, with proprietary technologies like Hypermatrix™, PODRAS™, and nPODDDS™ all engineered for controlled, biphasic, or abuse-deterrent drug release. These technologies allow our clients to differentiate their products, protect IP, and expand market access.

We navigate regulatory complexity with confidence, thanks to years of experience submitting and supporting ANDAs, NDAs, and global filings.

Learn more about our technologies

Collaborate with us

We actively work with pharmaceutical companies, biotech startups, research institutions, and technology developers to bring novel drug products to life. Our collaboration models range from joint development and co-investment programs to strategic supply and technology licensing partnerships. By aligning with organizations that share our scientific vision and commitment to patient impact, we create win-win opportunities that accelerate timelines and maximize therapeutic potential.

Whether you’re looking to outsource development, scale manufacturing, or co-develop a proprietary platform, Medicap brings the infrastructure, talent, and regulatory strength to move your project forward.

Connect with our Business Development team